Eli Lilly beats Novo Nordisk
Photo: Sean Krajacic/AP/TT

Eli Lilly beats Novo Nordisk as demand for Zepbound soars

U.S. drugmaker Eli Lilly, a competitor to Danish diet giant Novo Nordisk, is beating expectations.

Advertisement

If things are going well for Novo Nordisk, which beat forecasts on Tuesday evening, things are even better for Eli Lilly. Fourth-quarter profits were much better than expected as demand for its diet pill Zepbound soared.

Profit after tax came in at $6.6 billion, compared to $4.4 billion in the same period last year.

Management's forecast for the full year 2026 is also higher than analysts' forecasts.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All